At a glance
ClinicalIndex Comparison RecordPhase 4Terminated· 8 enrolled
Drug / intervention
Sodium Glycididazoledrug
Likely dose
Sodium Glycididazole 800mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Perspective Trial of Sodium Glycididazole Combined With Concurrent Chemoradiotherapy for Locally Recurrent Squamous Cell Esophageal Carcinoma
In Brief
A Phase 4 clinical trial evaluating Sodium Glycididazole for Esophageal Neoplasms. Terminated early, enrolled 8 participants across 9 sites.
Signals
Trial was terminated early
Detailed Summary
This is a perspective, multicenter,single arm, open study to evaluate the efficacy and safety of treatment with CMNa combined with concurrent chemoradiotherapy in patients with locally recurrent squamous cell esophageal carcinoma . Analyses of primary objective (ORR) will be done as defined in the protocol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Neoplasms
CountriesChina
Collaborators--
Timeline
Phase 4TerminatedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartJul 2016
Primary CompletionJun 2018
Study CompletionJul 2018
TodayJul 2026
First PostedMar 29, 2016
Enrollment StartJul 5, 2016
Primary CompletionJun 30, 2018
Study CompletionJul 30, 2018
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 10.3 years ago
Interventions
Sodium Glycididazoledrug
Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.